Board of Directors
Annette Bianchi joined the Neuraltus Board of Directors in March of 2009, bringing 30 years of venture capital experience to the organization. She is a Strategic Advisor for VantagePoint Capital Partners. Ms. Bianchi has significant expertise in many areas of investing, including medical devices, biotechnology and healthcare information technology and services. She began her career in venture capital in 1985 at Burr, Egan, Deleage & Company, later joining Weiss, Peck & Greer Venture Partners as a General Partner. In 1999, she became a Managing Director at Pacific Venture Group. Ms. Bianchi holds a B.S.E. and M.S.E. in Biomedical Engineering from University of Pennsylvania, and obtained an MBA from The Wharton School.
Rich Casey has more than 40 years of pharmaceutical and biotechnology industry experience and served as Neuraltus’ President and CEO from September 2013 through April 2018. From 1987 to 1998, Mr. Casey was Chairman and CEO of Scios, a biotechnology company working in the areas of cardiovascular disease, inflammation and Alzheimer’s disease. While at Scios, the company successfully developed Natrecor, a leading treatment for acute congestive heart failure in the United States. The company was sold to Johnson & Johnson in 2003 for $2.4 billion. Prior to Scios, Mr. Casey held a variety of marketing, sales and general management positions with Eli Lilly, Syntex and Alza. He holds a BS in Chemistry and a M.B.A. from Stanford University.
Don McGovern joined the Neuraltus Board of Directors in August of 2014 and is Chair of the Audit Committee. He brings more than 40 years of financial and accounting experience to Neuraltus. Mr. McGovern retired from Pricewaterhouse Coopers (PwC) in June 2013, following a 39-year career with the firm. During that time, he was Vice Chairman, Global Assurance at PwC, had directed the U.S. firm's services for a number of large public company clients and was involved in over 30 Silicon Valley IPOs. He also held various leadership roles in PwC and was, from July 2001 to June 2008, a member of, and past lead director for, the Board of Partners and Principals of the U.S. firm, as well as a member of PwC’s Global Board. Mr. McGovern currently serves as Senior Independent Director on the Board of Directors of CRH plc and is an Advisory Council Member of the Nasdaq Private Market. He is a member of the American Institute of Certified Public Accountants and holds a B.A. in history and political science from Marquette University and an M.B.A. from DePaul University.
Jim Woody, M.D., Ph.D.
Dr. Jim Woody joined the Neuraltus Board of Directors in March of 2009 with 25 years of healthcare-related research and development experience. Since 2006, Dr. Woody has been a partner at Latterell Venture Partners. He previously was founding CEO of OncoMed Pharmaceuticals (NASDAQ: OMED). Dr. Woody was formerly President of Roche Bioscience in Palo Alto, CA, and Chief Scientific Officer and Senior Vice President of R&D for Centocor, now Janssen Biotech. While at Centocor, Dr. Woody, along with colleagues, developed Remicade®, the first of the TNF inhibitor biologics and first effective therapy for rheumatoid arthritis, Crohn’s Disease and psoriasis. Prior to Centocor, he served as the Commanding Officer and Director, U.S. Naval Medical Research and Development Command in Bethesda, Maryland. Dr. Woody holds an M.D. from Loma Linda University, trained in Pediatric Immunology at Duke University and Children’s Hospital in Boston (Harvard) and holds a Ph.D. in Immunology from the University of London, England.